Linked Data API

Show Search Form

Search Results

1124922
unstar this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will make it his policy that NHS England include haemophilia as a condition area in the Getting It Right First Time programme. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251325 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>The Getting It Right First Time (GIRFT) programme aims to drive improvements in medical and surgical specialties through clinical leadership and the use of data to identify and reduce unwarranted variation in practice. By tackling variations in the way services are delivered across the National Health Service, and by sharing best practice between trusts, GIRFT identifies changes that will help improve care and patient outcomes, as well as delivering efficiencies such as the reduction of unnecessary procedures and cost savings.</p><p>Although there are no specific plans to include haemophilia as a condition area in the GIRFT programme currently, the ambition is that GIRFT will continue to expand to other medical specialities. Currently, areas are prioritised based on opportunity for improvements in patient care, suspected degree of variation and wide strategic priorities. Some examples of these work streams are lung cancer, paediatric critical care and neonatal intensive care.</p> more like this
star this property answering member constituency Wimbledon more like this
star this property answering member printed Stephen Hammond more like this
star this property question first answered
less than 2019-05-15T10:49:41.443Zmore like thismore than 2019-05-15T10:49:41.443Z
star this property answering member
1585
star this property label Biography information for Stephen Hammond more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
997127
unstar this property registered interest false more like this
star this property date less than 2018-10-29more like thismore than 2018-10-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, who the board members are for NHS England’s national tender for (a) factor VIII and (b) factor IX haemophilia products; which of those board members represent (i) the Northern Ireland Executive and (ii) organisations involved in Northern Ireland; and whether the board has met in Northern Ireland. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 184968 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-06more like thismore than 2018-11-06
star this property answer text <p>I refer the hon. Member to the answer I gave on 4 September 2018 to Question <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2018-07-23/167275/" target="_blank">167275</a>.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-06T15:19:19.77Zmore like thismore than 2018-11-06T15:19:19.77Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
997128
unstar this property registered interest false more like this
star this property date less than 2018-10-29more like thismore than 2018-10-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many people who were in receipt of (a) factor VIII and (b) factor IX Extended Half Life (EHLs) products had that treatment removed for (i) clinical and (ii) non-clinical reasons in 2017-18. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 184969 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-06more like thismore than 2018-11-06
star this property answer text <p>NHS England does not collect or hold information on the number of patients who have switched from Factor VIII and Factor IX Extended Half Life products to other treatments for clinical or non-clinical reasons in 2017-18.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-06T15:27:06.183Zmore like thismore than 2018-11-06T15:27:06.183Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
997129
unstar this property registered interest false more like this
star this property date less than 2018-10-29more like thismore than 2018-10-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 June 2018 to Question 154639 on Haemophilia: Medical Treatments, if he will make a comparative assessment of treatment uptake in (a) Ireland, (b) Canada and (c) the European Union. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 184970 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-06more like thismore than 2018-11-06
star this property answer text <p>There are currently no plans for an assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-06T15:15:28.69Zmore like thismore than 2018-11-06T15:15:28.69Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
997130
unstar this property registered interest false more like this
star this property date less than 2018-10-29more like thismore than 2018-10-29
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to Trigger 1 of NHS England’s Specialised Commissioning Briefing (Spring 2018), how the faster adoption of best value medicines requirement will affect the procurement of Extended Half Life factor VIII products; and which Factor VIII blood products will be covered by the Commissioning for Quality and Innovation. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 184971 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-06more like thismore than 2018-11-06
star this property answer text <p>I refer the hon. Member to the answer I gave on 4 September 2018 to Question <a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2018-07-23/167279/" target="_blank">167279</a>.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-11-06T15:28:22.22Zmore like thismore than 2018-11-06T15:28:22.22Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
985674
unstar this property registered interest false more like this
star this property date less than 2018-10-11more like thismore than 2018-10-11
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 September 2018 to Question 167276 on haemophilia: medical treatments, whether those savings have been reinvested in supporting the haemophilia community; and whether any savings in the devolved nations of the UK have accrued to (a) NHS England or (b) the devolved administrations. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
star this property uin 178261 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-18more like thismore than 2018-10-18
star this property answer text <p>The National Health Service achieves savings across all clinical services, and reinvests those savings within its overall expenditure limits set by parliament. The NHS does not usually ring fence funding for specific patient groups, but considers its funding responsibilities for all patients based on all sources of funding, including procurement savings. Savings from medicines used by the devolved administrations remain within those administrations.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-10-18T11:30:17.103Zmore like thismore than 2018-10-18T11:30:17.103Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
1533
star this property label Biography information for Diana Johnson more like this
987955
unstar this property registered interest false more like this
star this property date less than 2018-10-15more like thismore than 2018-10-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to commissioning criterion 6b of NHS England’s Criteria for the Prescribing of Enhanced Half-Life Blood Factors, published in September 2016; for what reason a maximum conversion ratio from Standard Half Life to EHL products was set; and whether a patient that achieved higher trough levels than before from a narrower conversion ratio would be switched back to their previous regimen. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
star this property uin 179162 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-18more like thismore than 2018-10-18
star this property answer text <p>The maximum conversion ratios were provided by clinical experts based on their experience of managing the clinical needs of most patients. Clinicians manage individual patients to achieve bleed control in line with the British Society of Haematology for trough levels, and bleed levels.</p><p> </p><p>The maximum conversion ratios apply only when switching from standard half-life (SHL) Factor IX (FIX) to and enhanced half-life (EHL) FIX. They do not apply when switching from an EHL FIX to an SHL FIX.</p><p> </p><p>Depending on individual patient need, it is possible that a patient could be switched to a previous or alternative regimen to achieve a target trough level greater than 1%.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-10-18T16:11:50.137Zmore like thismore than 2018-10-18T16:11:50.137Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
1533
star this property label Biography information for Diana Johnson more like this
987956
unstar this property registered interest false more like this
star this property date less than 2018-10-15more like thismore than 2018-10-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the paper entitled, The cost of severe haemophilia in Europe: the CHESS study published in the Orphanet journal of rare diseases in 2017, what assessment his Department has made of the reasons for (i) outcomes for patients and (ii) investment in treatments are lower in the UK than other EU5 countries; and what steps he is taking to improve treatment outcomes in the UK. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
star this property uin 179163 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-18more like thismore than 2018-10-18
star this property answer text <p>No such assessment has been made. The cost of blood factor products in the United Kingdom reflect successful commercial activities on price and clinical management such as universal access to prophylactic treatment regimens. These commercial activities enable the UK to achieve value for money when investing in providing access to treatment.</p><p> </p><p>The UK attracts many clinical studies in haemophilia, including those for new drugs or therapies which reduce the need for factor products altogether, based on its success in respect of managing haemophilia with prophylactic regimens.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-10-18T16:14:32.177Zmore like thismore than 2018-10-18T16:14:32.177Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
1533
star this property label Biography information for Diana Johnson more like this
987957
unstar this property registered interest false more like this
star this property date less than 2018-10-15more like thismore than 2018-10-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, with reference to the World Federation of Haemophilia’s annual global survey, published in 2016, for what reason (a) Factor VIII and (b) Factor IX consumption per capita is lower in the UK than Ireland; and what assessment he has made of the adequacy of UK levels of factor (i) VIII and (ii) IX consumption to deliver appropriate outcomes for patients. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
star this property uin 179164 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-18more like thismore than 2018-10-18
star this property answer text <p>NHS England commissions treatments for haemophilia A and haemophilia B, and other bleeding disorders, according to the current British Society for Haematology clinical guidelines. Commissioned services report outcomes via a quality dashboard. Based on the data, NHS England considers that haemophilia population outcomes are adequate, and therefore has not undertaken an assessment of the adequacy of factor levels. This will continue to be monitored as new data becomes available.</p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-10-18T16:08:22.363Zmore like thismore than 2018-10-18T16:08:22.363Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
1533
star this property label Biography information for Diana Johnson more like this
987959
unstar this property registered interest false more like this
star this property date less than 2018-10-15more like thismore than 2018-10-15
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will publish the timescale for the completion of the tenders for (a) Factor VIII and (b) Factor IX blood products. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
star this property uin 179165 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-10-18more like thismore than 2018-10-18
star this property answer text <p>The current Commercial Medicines Unit (CMU) framework agreements that cover the stated products run from the following dates and have the following expiry dates and extension options:</p><p> </p><p>- NHS Framework Agreement for the Supply of Recombinant Factor VIII products for the treatment of bleeding disorders – commencement date 1 February 2018 / expiry date 31 January 2019 with options to extend up to a further 17 months. The CMU are working towards extending this framework agreement;</p><p>- NHS National Framework Agreement for the supply of Human Cell Line Recombinant Factor VIII products for the treatment of bleeding disorders – commencement date 1 July 2016 / expiry date 31 January 2019 with options to extend up to a further 17 months. The CMU are working towards extending this framework agreement;</p><p>- NHS National Framework Agreement for the supply of Recombinant Factor IX Blood Clotting Factors – commencement date 1 September 2016 / expiry date 28 February 2019 with options to extend up to a further 18 months. This framework is due to be re-tendered with the anticipated publication date of the OJEU Notice being early November 2018, tender timescales will be dependent on when this notice is issued; and</p><p>- NHS Framework Agreement for the supply of products for the treatment of bleeding disorders – commencement date 1 July 2018 / expiry date 30 June 2019 with options to extend up to a further 36 months.</p>
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
star this property question first answered
less than 2018-10-18T16:15:12.793Zmore like thismore than 2018-10-18T16:15:12.793Z
star this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
1533
star this property label Biography information for Diana Johnson more like this